Papaverine
An alkaloid derived from the opium of the Papaver somniferum plant or prepared synthetically. Not structurally related to the rest of opium alkaloids such as morphine or codeine.
It has a relaxant effect on the vascular system, bronchial musculature and the gastrointestinal, biliary and urinary tracts (American Regent 2017).
Indicated in coronary, pulmonary, peripheral or cerebral vascular spasms and gastrointestinal, ureteral or biliary colic. Oral, intramuscular or intravenous administration every 3 to 12 hours.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (large volume of distribution, high percentage of protein binding, short half-life, pKa acid) make transfer to milk in significant quantities unlikely.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Alternatives
- Otilonium Bromide (Very Low Risk)
- Atropine (Very Low Risk)
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Synonyms
- Papaverine Hydrochloride
Writings
- Παπαβερίνη (Greek)
- Папаверин (Cyrillic)
- パパベリン (Japanese)
- C20 H21 NO4 (Molecular formula)
- 6,7-Dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline (Chemical name)
- A03AD01; G04BE02 (ATC Code/s)
Drug trade names
References
- American Regent. Papaverine. Drug Summary. 2017 Full text (in our servers)
- AcoFarma. Papaverina. Ficha técnica. 2010 Full text (in our servers)
- Berg G, Jönsson KA, Hammar M, Norlander B. Variable bioavailability of papaverine. Pharmacol Toxicol. 1988Abstract
- Wilén G, Ylitalo P. Metabolism of [14C] papaverine in man. J Pharm Pharmacol. 1982Abstract Full text (link to original source)
- Garrett ER, Roseboom H, Green JR Jr, Schuermann W. Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. Int J Clin Pharmacol Biopharm. 1978Abstract
- Ritschel WA, Hammer GV. Pharmacokinetics of papaverine in man. Int J Clin Pharmacol Biopharm. 1977Abstract